Co-Delivery of erlotinib and resveratrol via nanostructured lipid Carriers: A synergistically promising approach for cell proliferation prevention and ROS-Mediated apoptosis activation

Asadollahi, Leila; Mahoutforoush, Amin; Dorreyatim, Seyed Sina; Soltanfam, Tannaz; Paiva‐Santos, Ana Cláudia; Peixoto, Diana; Veiga, Francisco; Hamishehkar, Hamed; Zeinali, Mahdi; Abbaspour‐Ravasjani, Soheil

doi:10.1016/j.ijpharm.2022.122027

Cited by 27 publications

(7 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The more selective and efficient anticancer treatment strategies have opened promising horizons in increasing cancer patients' survival rates. Drug delivery systems containing the encapsulated bioactive compound have been widely applied in recent research (Asadollahi et al 2022;Zeinali et al 2021;Piazzini et al 2019;Mansoori et al 2020). To the best of our knowledge, this is the first time producing a novel dynamic delivery system simulating the enzymatic effectors of innate immune cell response called human immune simulating anti-breast cancer-nanorobot (hisABC-NB) and analyzing its apoptotic, selectivity, cytotoxicity, and MRI-traceability.…”

Section: Discussionmentioning

confidence: 99%

“…Also, their biocompatibility and serum solubility make them more efficient (Jahan et al 2021). In this regard, nanoparticles targeting breast cancer cell receptors such as EGFR- (Milane et al 2011), Folate Receptor- (Alibolandi et al 2016), and HER-2 (Kim et al 2020) targeted drug-loaded NPs have been synthesized for the efficient delivery of anti-breast cancer compounds (Asadollahi et al 2022).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The human immune cell simulated anti-breast cancer nanorobot: the efficient, traceable, and dirigible anticancer bio-bot

2022

View full text Add to dashboard Cite

Background Various types of cancer therapy strategies have been investigated and successfully applied so far. There are a few modern strategies for improving drug selectivity and biocompatibility, such as nanoparticle-based drug delivery systems. Herein, we designed the traceable enzyme-conjugated magnetic nanoparticles to target human breast cancer cells by simulating the innate immune cell’s respiratory explosion response. Methods The human immune cell simulated anti-breast cancer-nanorobot (hisABC-NB) was produced by conjugating the mouse-derived iNOS and human-originated MPO enzymes on the folate-linked chitosan-coated Fe3O4 nanoparticles. The synthesized nanoparticles were functionalized with folic acid as the breast cancer cell detector. Then, the hisABC-NB’s stability and structural properties were characterized by studying Zeta-potential, XRD, FTIR, VSM, FESEM, and DLS analysis. Next, the selectivity and anti-tumor activity of the hisABC-NB were comparatively analyzed on both normal (MCF-10) and cancerous (MCF-7) human breast cells by analyzing the cells’ survival, apoptotic gene expression profile (P53, BAX, BCL2), and flow cytometry data. Finally, the hisABC-NB’s traceability was detected by T2-weighted MRI imaging on the balb-c breast tumor models. Results The hisABC-NB significantly reduced the MCF-7 human breast cancer cells by inducing apoptosis response and arresting the cell cycle at the G2/M phase compared with the normal cell type (MCF-10). Moreover, the hisABC-NB exhibited a proper MRI contrast at the tumor region of treated mice compared with the non-treated type, which approved their appropriate MRI-mediated traceability. Conclusion The hisABC-NB’s traceability, dirigibility, and selective cytotoxicity were approved, which are the three main required factors for an efficient anticancer compound. Therefore, it has the potential to be used as an intelligent safe anticancer agent for human breast cancer treatment. However, several in vitro and in vivo studies are required to clarify its selectivity, stability, and safety.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The human immune cell simulated anti-breast cancer nanorobot: the efficient, traceable, and dirigible anticancer bio-bot

2022

View full text Add to dashboard Cite

show abstract

“…Particle size and zeta potential of nanoethosomal formulations were assessed by laser diffraction technique (Nano ZS, Malvern, UK). Scanning electron microscope (SEM) (MIRA3 TESCAN, UK, LEO 84 1430VP, UK & Germany) was conducted at 15 kV [ 19 ].…”

Section: Methodsmentioning

confidence: 99%

The navel nanoethosomal formulation of gamma-oryzanol attenuates testicular ischemia/reperfusion damages

Khormali,

Farahpour

2024

Heliyon

View full text Add to dashboard Cite

“…Natural phytochemicals have many outstanding and versatile bioactivities like anticancer or chemo sensitizing effect . Recent advances have witnessed the enhanced anticancer performances by EGFR-TKI combination with epigallocatechin-3-gallate, curcumin, , quercetin, , natural borneol, thymoquinone, resveratrol, artesunate (antimalaria drug), and capsaicin . In a recent study, Ganthala et al found that Erlo plus quercetin showed synergistic inhibition of lung cancer while the other combinations (fisetin, carnosic acid, or luteolin) of Erlo did not .…”

Section: Egfr-tki-based Combinational Cancer Therapymentioning

confidence: 99%

Recent Advances in Boosting EGFR Tyrosine Kinase Inhibitors-Based Cancer Therapy

Pan

et al. 2023

Mol. Pharmaceutics

View full text Add to dashboard Cite

Epidermal growth factor receptor (EGFR) plays a key role in signal transduction pathways associated with cell proliferation, growth, and survival. Its overexpression and aberrant activation in malignancy correlate with poor prognosis and short survival. Targeting inhibition of EGFR by small-molecular tyrosine kinase inhibitors (TKIs) is emerging as an important treatment model besides of chemotherapy, greatly reshaping the landscape of cancer therapy. However, they are still challenged by the offtargeted toxicity, relatively limited cancer types, and drug resistance after long-term therapy. In this review, we summarize the recent progress of oral, pulmonary, and injectable drug delivery systems for enhanced and targeting TKI delivery to tumors and reduced side effects. Importantly, EGFR-TKI-based combination therapies not only greatly broaden the applicable cancer types of EGFR-TKI but also significantly improve the anticancer effect. The mechanisms of TKI resistance are summarized, and current strategies to overcome TKI resistance as well as the application of TKI in reversing chemotherapy resistance are discussed. Finally, we provide a perspective on the future research of EGFR-TKI-based cancer therapy.

show abstract

Co-Delivery of erlotinib and resveratrol via nanostructured lipid Carriers: A synergistically promising approach for cell proliferation prevention and ROS-Mediated apoptosis activation

Cited by 27 publications

References 46 publications

The human immune cell simulated anti-breast cancer nanorobot: the efficient, traceable, and dirigible anticancer bio-bot

The human immune cell simulated anti-breast cancer nanorobot: the efficient, traceable, and dirigible anticancer bio-bot

The navel nanoethosomal formulation of gamma-oryzanol attenuates testicular ischemia/reperfusion damages

Recent Advances in Boosting EGFR Tyrosine Kinase Inhibitors-Based Cancer Therapy

Contact Info

Product

Resources

About